- Home
- IPSC vs MDCX Comparison
IPSC vs MDCX Comparison
Compare IPSC & MDCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPSC
- MDCX
- Stock Information
- Founded
- IPSC 2019
- MDCX 2008
- Country
- IPSC United States
- MDCX Canada
- Employees
- IPSC N/A
- MDCX N/A
- Industry
- IPSC Medicinal Chemicals and Botanical Products
- MDCX
- Sector
- IPSC Health Care
- MDCX
- Exchange
- IPSC Nasdaq
- MDCX Nasdaq
- Market Cap
- IPSC 42.2M
- MDCX 36.2M
- IPO Year
- IPSC 2021
- MDCX N/A
- Fundamental
- Price
- IPSC $0.49
- MDCX $1.94
- Analyst Decision
- IPSC Strong Buy
- MDCX Strong Buy
- Analyst Count
- IPSC 5
- MDCX 2
- Target Price
- IPSC $3.33
- MDCX $23.50
- AVG Volume (30 Days)
- IPSC 698.6K
- MDCX 408.7K
- Earning Date
- IPSC 08-14-2025
- MDCX 08-11-2025
- Dividend Yield
- IPSC N/A
- MDCX N/A
- EPS Growth
- IPSC N/A
- MDCX N/A
- EPS
- IPSC N/A
- MDCX N/A
- Revenue
- IPSC $114,128,000.00
- MDCX N/A
- Revenue This Year
- IPSC $1,589.94
- MDCX N/A
- Revenue Next Year
- IPSC N/A
- MDCX N/A
- P/E Ratio
- IPSC N/A
- MDCX N/A
- Revenue Growth
- IPSC 5491.77
- MDCX N/A
- 52 Week Low
- IPSC $0.34
- MDCX $1.80
- 52 Week High
- IPSC $1.86
- MDCX $8.94
- Technical
- Relative Strength Index (RSI)
- IPSC 37.35
- MDCX 38.69
- Support Level
- IPSC $0.46
- MDCX $1.88
- Resistance Level
- IPSC $0.55
- MDCX $2.27
- Average True Range (ATR)
- IPSC 0.04
- MDCX 0.26
- MACD
- IPSC -0.00
- MDCX 0.02
- Stochastic Oscillator
- IPSC 25.00
- MDCX 19.40
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.